RIT study of 177Lu-anti-ROBO1 IgG for small cell lung cancer

2017 Fiscal Year Final Research Report

• Project/Area Number: 16K19809
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Radiation science
• Research Institution: National Institutes for Quantum and Radiological Science and Technology (2017); The University of Tokyo (2016)
• Principal Investigator: Fujiwara Kentaro 国立研究開発法人量子科学技術研究開発機構, 放射線医学総合研究所 分子イメージング診断治療研究部, 博士研究員(任常) (80766907)
• Research Collaborator: HAMAKUBO Takao
• Project Period (FY): 2016-04-01 – 2018-03-31
• Keywords: 放射免疫療法 / 小細胞肺がん

Outline of Final Research Achievements

Small cell lung cancer (SCLC) xenograft mice was treated by Lu-177-labeled anti-ROBO1 IgG which is an agent of radioimmunotherapy (RIT). However, no significant therapeutic effect was observed.
Sulfasarazine is a candidate therapeutic agent for cancer stem cell. We performed a combination therapy of RIT using Y-90-labeled anti-ROBO1 IgG and sulfasarazine against SCLC xenograft mice. Although there was no significant differences between the therapeutic effect of RIT only group and that of the combination group, a remarkable tumor shrinkage was observed in both groups. In the RIT only group, a complete response was observed.

Free Research Field

核医学